Developed in 1974 and approved in Russia in 1982, Thymalin is primarily manufactured as a clinical drug by Samson-Med or sold globally online by peptide vendors as a research chemical. It is supplied as a lyophilized powder that must be reconstituted for subcutaneous or intramuscular injection, as oral digestion destroys its active peptides. Clinically, it is used as an immunocorrecter to treat severe immune deficiencies, acute or chronic viral and bacterial infections, tissue damage from burns, bone marrow suppression after chemotherapy, and age-related immune decline.